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New aspects of supportive care: The MASCC vision
Jﬂrn Herrstedt
ABSTRACT
The Multinational Association of Supportive Care in Cancer (MASCC) was founded in 1991, and joined
forces with the International Society of Oral Oncology (ISOO) in 1998. The "mission" of MASCC is to opti-
mize supportive care in cancer patients worldwide, stimulate multi-disciplinary research, encourage
international scientific exchange of information, expand professional expertise in supportive care, edu-
cate health care professionals worldwide in supportive care, and to serve as a resource for patients, fam-
ilies, and caregivers. Ten years ago, the most frequently addressed supportive care symptoms included
pain, febrile neutropenia, and the prevention of nausea and vomiting. These topics are still indeed rele-
vant for cancer patients, but today focus has also turned to topics such as mucositis, and specific sup-
portive care problems in the elderly. Recent, studies have indicated that individually targeted supportive
care therapy might become an important part of clinical practice in the near future.
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T
he Multinational Association of Supportive Care in Cancer (MASCC) was founded in
1991 and the first issue of the journal of Supportive Care in Cancer was released in
January 1993. In 1998 MASCC and the International Society of Oral Oncology (ISOO) joined
forces, and today MASCC/ISOO has grown and includes more than 700 members through-
out the world. The Journal was, in 1993, published bi-monthly, but as of 2003 members
and other subscribers receive 12 issues of the Journal per year.  
In 1993 supportive care was defined as: "The comprehensive medical, nursing and psy-
chosocial help that the patients need besides specific therapy of cancer" (1). This definition
has recently been modified to emphasize the continuum of support that is often necessary
whether the patient is cured or eventually dies from the cancer disease. The definition is
today: "Supportive care is the prevention and management of the adverse effects of cancer
and its treatment. This includes physical and psychosocial symptoms and side effects
across the entire continuum of the cancer experience including the enhancement of reha-
bilitation and survivorship" (2).
The "mission" of MASCC is to optimize supportive care in cancer patients worldwide, stim-
ulate multi-disciplinary research, encourage international scientific exchange of information,
expand professional expertise in supportive care, educate health care professionals world-
wide in supportive care, and to serve as a resource for patients, families, and caregivers.
These goals are achieved through annual strategic planning meetings, annual symposia and
through development of evidence-based clinical practice guidelines. The "tools" are the mul-
tidisciplinary study groups of MASCC dealing with supportive care topics such as antiemet-
ics, cytokines, health outcomes, infection, intensive care, metabolism and nutrition,
mucositis, pain, patient education, quality of life, and vascular access.
The need for supportive care changes during the different phases of a cancer patients’ dis-
ease (Figure 1). At the time of cancer diagnosis and start of treatment (curative phase),
patients, e.g., need effective antiemetic prophylaxis and antibiotics in case of febrile neu-
tropenia. Patients, who are no longer receiving curative intended therapy (palliative phase),
often have a need for analgesics, and in the last weeks of a cancer patients’ life, problems
such as confusion and dehydration become frequent.
Today, approximately 60% of cancer patients survive more than 5 years from the time of
diagnosis. The effects of cancer itself and the chronic toxicity from cancer therapy can
adversely affect patients’ physical, psychological and social function (3), emphasizing the
need for research in rehabilitation of cancer patients (rehabilitation phase). In Table 1, a list
of supportive care problems is given. 
Ten years ago, the most frequently addressed supportive care symptoms included pain,
febrile neutropenia, and the prevention of nausea and vomiting. These areas of supportive
care have developed differently. Pain research has primarily focused on new administration
forms of well-known drugs and different pain syndromes including breakthrough pain (4),
but still many patients are inadequately treated. The development in the management of
febrile neutropenia has focused on new antibiotics but also on more simple schedules going
from combination antibiotic therapy to monotherapy, and from inpatient therapy to outpa-
Figure 1. Phases of Supportive Caretient oral treatment of well-defined low risk groups (5). The prevention of acute chemother-
apy-induced emesis has been revolutionized by the use of serotonin3-receptor antagonists,
and a new group of antiemetics, the neurokinin1-receptor antagonists, have further opti-
mized antiemetic prophylaxis, thereby improving quality of life in patients receiving
chemotherapies (6). Consequently a recent consensus conference, with the participation of
25 investigators, representing 9 different cancer organizations (including MASCC), has
updated the 1997 MASCC guidelines. The updated guidelines are already published on the
MASCC web site (2) and will soon appear in the journal of Supportive Care in Cancer.  
In the past few years new areas of supportive care have emerged. The alliance between
MASCC and ISOO has resulted in highly effective integration of science used in the inves-
tigation of mucositis and in the development of evidence-based guidelines (7). Also sup-
portive care in the elderly has become a major focus area. The elderly population increas-
es and it has for years been recognized, that elderly patients with cancer deserve special
attention, whether they receive therapy with curative intent or they need palliative therapy
for terminal cancer (8).       
Pharmacogenetic research has led to the development of individually targeted therapy for
some cancer diseases. E.g. the understanding that a single factor, such as mutations in the
tyrosine kinase moiety of the epidermal growth factor, is responsible for tumor growth, has
led to the development of drugs like imatinib (chronic myeloid leukemia and gastrointesti-
nal stromal tumors) and gefitinib (lung cancer). The recognition that variations in the meta-
bolic pathways of cytotoxins and supportive care drugs (e.g., antiemetics) are clinically rel-
evant, has led to the exploration of molecular targets for the improvement of symptom man-
agement. Innocenti and coworkers recently published a trial investigating the significance
of genetic variants in the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene. They showed
that variation in this gene predicted the risk of severe neutropenia after treatment with
irinotecan, a drug using UGT1A1 in its metabolic pathway (9). The importance of the
cytochrome P-450 enzyme system has also been verified in the antiemetic setting.
Competition for the same metabolic pathways and gene variations can in theory lead to
either rapid metabolism, and thereby a decrease in the effect of an antiemetic, or to poor
metabolism, resulting in increased toxicity. Kaiser et al. investigated 270 patients receiving
chemotherapy and antiemetic therapy with a 5-HT3 receptor antagonist (tropisetron or
ondansetron) known to be metabolized through the CYP2D6 isoenzyme (10). They geno-
typed the patients and showed that genetically defined ultrarapid metabolizers had a high-
er frequency of vomiting than all other patients. They concluded that antiemetic therapy with
a 5-HT3 receptor antagonist could be improved by adjustment for the CYP2D6 genotype.
In the future, when genotyping methods become cheaper and consequently generally avail-
able, individually targeted supportive care therapy will probably become an important part
of clinical practice.
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Table 1. Topics in Supportive Care of Cancer